Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal cancer
• * Recurrent disease
• Received no more than 4 prior chemotherapy regimens for this malignancy
• * Considered refractory or resistant to prior taxane (paclitaxel or docetaxel) and/or platinum (cisplatin or carboplatin) therapy based on 1 of the following criteria:
• * Treatment-free interval \< 6 months after platinum or paclitaxel
• * Disease progression during platinum- or paclitaxel-based therapy
• Measurable or evaluable disease
• * Measurable disease is defined as at least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
• * Evaluable disease is defined as doubling of CA 125 blood levels within the past 6 months AND CA 125 level ≥ 2 times upper limit of normal (ULN) within the past week
• No active CNS metastases
• * Patients with known CNS metastases must have received prior radiotherapy or CNS-directed chemotherapy AND have ≥ 4 weeks of stable disease
• PATIENT CHARACTERISTICS:
• Age
• Over 18
• Performance status
• Karnofsky 60-100%
• Life expectancy
• At least 3 months
• Hematopoietic
• Neutrophil count \> 1,500/mm\^3
• Platelet count \> 100,000/mm\^3
• WBC \> 3,000/mm\^3
• Hematocrit ≥ 28% (transfusion or growth factors allowed)
• Hemoglobin \> 8.0 g/dL (transfusion or growth factors allowed)
• Hepatic
• Bilirubin ≤ 1.5 times ULN
• SGOT ≤ 2.5 times ULN
• Alkaline phosphatase ≤ 2.5 times ULN
• Renal
• Creatinine ≤ 1.5 times ULN
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No active infection requiring antibiotics
• No neuropathy (sensory or motor) \> grade 1
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No concurrent immunotherapy
• Chemotherapy
• See Disease Characteristics
• No other concurrent chemotherapy
• Endocrine therapy
• No concurrent hormonal therapy for the malignancy
• Radiotherapy
• See Disease Characteristics
• No prior whole abdominal radiotherapy
• Concurrent localized radiotherapy allowed for control of local complications not indicative of general disease progression
• Surgery
• Not specified
• Other
• Recovered from prior antineoplastic therapy
• More than 4 weeks since prior standard therapy for malignant tumor
• More than 6 months since prior investigational anticancer drugs
• No other concurrent investigational drugs
• No concurrent drugs significantly metabolized by the cytochrome P450 enzymes CYP2C8, CYP2C9, CYP2C19, and CYP3A4/B1C
• No concurrent amifostine or other protective agents
• No concurrent grapefruit juice